KDM6B调控MAPK通路介导多发性骨髓瘤细胞生长与存活
本研究显示KDM6B在多发性骨髓瘤(MM)细胞中表达,shRNA敲低和CRISPR敲除KDM6B可抑制MM细胞生长与存活。TNF-α或骨髓基质细胞培养上清诱导KDM6B,该诱导可被IKKβ抑制剂MLN120B阻断,提示NF-κB信号调控KDM6B。RNA-seq和ChIP-qPCR显示KDM6B被招募至MAPK通路组分ELK1和FOS基因位点并上调其表达,且不改变H3K27甲基化水平;过表达催化失活型KDM6B仍激活MAPK通路相关基因,证实其功能不依赖去甲基化酶活性。ELK1和FOS赋予MM细胞生长能力。研究揭示KDM6B连接NF-κB与MAPK信号通路介导MM细胞生长与存活,并验证KDM6B为MM新型治疗靶点。
要点
- KDM6B在MM细胞中表达,敲低或敲除KDM6B可抑制MM细胞生长与存活。
- TNF-α或骨髓基质细胞培养上清经NF-κB信号诱导KDM6B,可被IKKβ抑制剂MLN120B阻断。
- KDM6B被招募至ELK1和FOS基因位点并上调其表达,不改变H3K27甲基化水平。
核心结论
- KDM6B连接NF-κB与MAPK信号通路介导MM细胞生长与存活,并被验证为MM新型治疗靶点。
研究设计与样本
- 本研究在MM细胞中进行shRNA介导的敲低和CRISPR介导的敲除实验,并结合RNA-seq和ChIP-qPCR分析。
主要发现
- shRNA介导的KDM6B敲低和CRISPR介导的KDM6B敲除可抑制MM细胞生长与存活。
- 肿瘤坏死因子-α或骨髓基质细胞培养上清诱导KDM6B,该诱导可被IKKβ抑制剂MLN120B阻断。
- RNA-seq和ChIP-qPCR分析显示KDM6B被招募至编码MAPK信号通路组分包括ELK1和FOS的基因位点,并上调这些基因表达,而不影响H3K27甲基化水平。
- 过表达催化失活型KDM6B激活MAPK通路相关基因表达,证实其功能不依赖去甲基化酶活性。
- KDM6B下游靶点ELK1和FOS赋予MM细胞生长能力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have delineated cancer-type-specific roles of histone 3 lysine 27 (H3K27) demethylase KDM6B/JMJD3 depending on its H3K27 demethylase activity. Here we show that KDM6B is expressed in multiple myeloma (MM) cells; and that shRNA-mediated knockdown and CRISPR-mediated knockout of KDM6B abrogate MM cell growth and survival. Tumor necrosis factor-α or bone marrow stromal cell culture supernatants induce KDM6B, which is blocked by IKKβ inhibitor MLN120B, suggesting that KDM6B is regulated by NF-κB signaling in MM cells. RNA-seq and subsequent ChIP-qPCR analyses reveal that KDM6B is recruited to the loci of genes encoding components of MAPK signaling pathway including ELK1 and FOS, and upregulates expression of these genes without affecting H3K27 methylation level. Overexpression of catalytically inactive KDM6B activates expression of MAPK pathway-related genes, confirming its function independent of demethylase activity. We further demonstrate that downstream targets of KDM6B, ELK1 and FOS, confer MM cell growth. Our study therefore delineates KDM6B function that links NF-κB and MAPK signaling pathway mediating MM cell growth and survival, and validates KDM6B as a novel therapeutic target in MM.
引用
- Ohguchi H, Harada T, Sagawa M, et al. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 2017. PMID: 28487543. doi:10.1038/leu.2017.141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。